Bluebird prices gene therapy at 1.575 mln euros over five years
June 14, 2019 at 08:00 AM EDT
Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.575 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.